A 2025-founded medtech venture developing mixed-matrix membranes that combine diffusion and adsorption in one dialyzer. The platform targets higher uremic-toxin clearance, lower dialysate consumption, and eventual wearable artificial-kidney applications. This is a particularly direct collaboration/licensing lead for Baxter: engage on hollow-fiber/module integration, hemocompatibility and albumin-retention testing, scale-up, and co-development of a next-generation dialyzer.
M3Nephron B.V. is a 2025 spin-off from the University of Twente, Netherlands. The company focuses on the development and commercialization of innovative membrane technologies to improve hemodialysis treatment, aiming to enhance patient outcomes, reduce healthcare costs, and increase the accessibility of home-based and portable dialysis solutions.